 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- izeltabart tapatansine (IMGC936) / MacroGenics, AbbVie
Results from a phase 1/2, first-in-human, dose escalation and dose expansion study of an investigational anti-ADAM9 antibody-drug conjugate IMGC936 in patients with advanced solid tumors (Exhibition Hall) - Sep 7, 2024 - Abstract #EORTCNCIAACR2024EORTC_NCI_AACR_264;
Unless they are part of the media programme, embargoed or not consented, all abstracts will be released on 9 October 2024. All other abstracts will be released on the day of presentation.
- ||| izeltabart tapatansine (IMGC936) / MacroGenics, AbbVie
Trial completion, Enrollment change, Trial completion date, Metastases: First-in-Human Study of IMGC936 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 14, 2024
P1/2, N=56, Completed, Sponsor: ImmunoGen, Inc.
All other abstracts will be released on the day of presentation. Recruiting --> Completed | N=245 --> 56 | Trial completion date: Apr 2024 --> Dec 2023
- | IMGC936 / ImmunoGen, MacroGenics
Preclinical, Journal: Preclinical Evaluation of IMGC936, a Next Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors. (Pubmed Central) - Jul 9, 2022
P1/2
Our preclinical data provide a strong scientific rationale for the further development of IMGC936 as a therapeutic candidate for the treatment of ADAM9-positive cancers. A first-in-human study of IMGC936 in patients with advanced solid tumors has been initiated (NCT04622774).
- IMGN151 / ImmunoGen, IMGC936 / ImmunoGen, MacroGenics
[VIRTUAL] Next-generation ADCs (IMGN151 & IMGC936) () - Sep 23, 2021 - Abstract #ADCUSA2021ADC_USA_96;
A first-in-human study of IMGC936 in patients with advanced solid tumors has been initiated (NCT04622774). Innovated next-generation ADCs IMGN151 is a next generation FRα-targeting ADC engineered to include multiple technological innovations to maximize the potential clinical benefit for patients with a broad range of target expression IMGC936 is an investigational ADAM9-targeting ADC, comprised of a high-affinity humanized monoclonal antibody site-specifically coupled to DM21
- ||| izeltabart tapatansine (IMGC936) / MacroGenics, AbbVie
Phase classification, Enrollment change, Trial completion date, Trial primary completion date, Metastases: First-in-Human Study of IMGC936 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jun 9, 2021
P1/2, N=245, Recruiting, Sponsor: ImmunoGen, Inc.
Innovated next-generation ADCs IMGN151 is a next generation FRα-targeting ADC engineered to include multiple technological innovations to maximize the potential clinical benefit for patients with a broad range of target expression IMGC936 is an investigational ADAM9-targeting ADC, comprised of a high-affinity humanized monoclonal antibody site-specifically coupled to DM21 Phase classification: P1 --> P1/2 | N=42 --> 245 | Trial completion date: Oct 2021 --> Apr 2024 | Trial primary completion date: Jul 2021 --> Oct 2023
- IMGC936 / ImmunoGen, MacroGenics
[VIRTUAL] IMGC936, an investigational ADAM9-targeting antibody drug conjugate, is active against patient-derived ADAM9-expressing xenograft models () - Mar 11, 2021 - Abstract #AACR2021AACR_3290;
P1
A majority of the tumor samples had medium to high levels of ADAM9 with 62% of non-small cell lung carcinoma (NSCLC), 65% of triple negative breast cancer (TNBC), 73% of gastric cancer, and 85% of pancreatic cancer samples having H- scores of 101 to 300. The remaining tumor samples had lower levels of ADAM9 expression (H-score 1 to 100) with only 1.2% of NSCLC samples being ADAM9-negative.
- || izeltabart tapatansine (IMGC936) / MacroGenics, AbbVie
New P1 trial, Metastases: First-in-Human Study of IMGC936 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Nov 9, 2020
P1, N=42, Recruiting, Sponsor: ImmunoGen, Inc.